Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Closed testing procedure

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Closed testing procedure. Displaying page 1 of 1.
    EudraCT Number: 2017-001319-36 Sponsor Protocol Number: FIERCE-21(B-701-U21) Start Date*: 2017-08-23
    Sponsor Name:BioClin Therapeutics, Inc.
    Full Title: A Dose Escalation, Expansion Study of Vofatamab (B 701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects with Locally Advanced or Metastatic Urothelial Cell Carcinoma who have Relapsed After,...
    Medical condition: Treatment of progressed or refractory metastatic UCC
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001522-41 Sponsor Protocol Number: PACT2014-001 Start Date*: 2016-02-08
    Sponsor Name:University Hospital Wuerzburg
    Full Title: Prophylactic application of donor-derived central memory T lymphocytes (TCM) after allogeneic HSCT to prevent infectious complications
    Medical condition: patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after T cell depleted allo-SCT
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028555 Myeloid leukemia LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001248-30 Sponsor Protocol Number: XRP1526B/3031 Ciclesidone Start Date*: 2006-06-16
    Sponsor Name:Sanofi-Aventis U.S. Inc.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 μg administered either in a once-...
    Medical condition: Asthma is a chronic inflammatory disease of the airways characterized by airway hyperresponsiveness, acute and chronic bronchoconstriction, airway edema, and mucus plugging. The inflammatory compon...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000592-24 Sponsor Protocol Number: MR308-3501 Start Date*: 2017-03-15
    Sponsor Name:Mundipharma Research GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Multicenter, Placebo- and active Comparator-Controlled Study to evaluate Efficacy and Safety of MR308 in the Treatment of Acute Pain After Third Molar Tooth Extraction (...
    Medical condition: Acute pain after third molar tooth extraction; dental procedure must have involved extraction of at least two impacted third molars requireing bone removal. If only two impacted third molars are ex...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000023314 10066714 Acute pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005244-17 Sponsor Protocol Number: GED-0507-ACN-01-14 Start Date*: 2015-09-28
    Sponsor Name:PPM SERVICES S.A.
    Full Title: AN OPEN LABEL CLINICAL STUDY TO EVALUATE THE LONG-TERM DERMAL SAFETY PROFILE OF 12-WEEKS TOPICAL ADMINISTRATION OF TWO DIFFERENT DOSES OF N-ACETYL-GED-0507-34-LEVO GEL IN PATIENTS WITH MILD TO MODE...
    Medical condition: Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003469-24 Sponsor Protocol Number: SPI-GCF-302 Start Date*: 2017-03-14
    Sponsor Name:Spectrum Pharmaceuticals, Inc.
    Full Title: Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage BReast Cancer Patients Receiving D...
    Medical condition: Management of Neutropenia in Patients with Breast Cancer who receiving Chemotherapy with the Docetaxel + Cyclophosphamide
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10029354 Neutropenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-005478-22 Sponsor Protocol Number: PCYC-1127-CA Start Date*: 2014-07-04
    Sponsor Name:Pharmacyclics, Incorporated
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects with Previously Treated Waldenstrom’s Macroglobulinemia
    Medical condition: Relapsed or refractory Waldenstrom’s Macroglobulinemia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047804 Waldenstrom's macroglobulinaemia recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) ES (Completed) GR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-005008-32 Sponsor Protocol Number: ICORG13-17 Start Date*: 2014-07-16
    Sponsor Name:Cancer Trials Ireland
    Full Title: A phase II Study of the Efficacy and Safety of lenalidomide, subcutaneous bortezomib, and dexamethasone combination therapy for patients with newly diagnosed multiple myeloma
    Medical condition: Newly diagnosed multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022548-19 Sponsor Protocol Number: TP-434-P2-cIAI-1 Start Date*: 2011-05-09
    Sponsor Name:Tetraphase Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of 2 Dose Regimens of TP-434 Compared with Ertapenem in Adult...
    Medical condition: Community-acquired complicated intra-abdominal infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10056570 Intra-abdominal infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) BG (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000593-38 Sponsor Protocol Number: MR308-3502 Start Date*: 2016-12-05
    Sponsor Name:Mundipharma Research GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Multicenter, Placebo- and active Comparator-Controlled Study to evaluate Efficacy and Safety of MR308 in the Treatment of Acute Pain After Abdominal Hysterectomy Surgery...
    Medical condition: Acute pain after open total or subtotal abdominal hysterectomy
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004867 10066714 Acute pain LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed) SK (Completed) LV (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-005413-23 Sponsor Protocol Number: CY4031 Start Date*: 2016-05-20
    Sponsor Name:Cytokinetics, Inc.
    Full Title: A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients with Amyotroph...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IE (Completed) NL (Completed) ES (Completed) PT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003996-37 Sponsor Protocol Number: WSG-AM09 Start Date*: 2019-12-10
    Sponsor Name:Westdeutsche Studiengruppe GmbH (WSG)
    Full Title: A prospective, multicenter, open label, neoadjuvant phase II single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer p...
    Medical condition: HER 2+/HR+ and HR- early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10006188 Breast cancer female NOS LLT
    20.0 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005055-14 Sponsor Protocol Number: P7977-1231 Start Date*: 2012-03-19
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks...
    Medical condition: Chronic Genotype 2 or 3 HCV Infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) EE (Completed) IT (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003307-19 Sponsor Protocol Number: NAC-GED-0507-ACN-01-18 Start Date*: 2019-09-18
    Sponsor Name:PPM SERVICES S.A.
    Full Title: A double-blind, randomized, vehicle-controlled clinical multi-center study to evaluate the efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel, 2 and 5%, applied once daily for 12 weeks in patient...
    Medical condition: facial acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000496 Acne PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002560-16 Sponsor Protocol Number: 747-303 Start Date*: 2015-12-10
    Sponsor Name:Intercept Pharmaceuticals Inc.
    Full Title: A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
    Medical condition: Nonalcoholic steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004871 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) AT (Completed) SE (Completed) BE (Completed) DK (Completed) ES (Completed) FI (Completed) PT (Prematurely Ended) HU (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003277-42 Sponsor Protocol Number: MCLA-128-CL01 Start Date*: 2015-01-13
    Sponsor Name:Merus B.V.
    Full Title: A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors
    Medical condition: Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Ongoing) FR (Trial now transitioned) PT (Completed) NO (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003581-27 Sponsor Protocol Number: CA209-9UT Start Date*: 2020-07-03
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Ca...
    Medical condition: BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005220-33 Sponsor Protocol Number: D1690C00004 Start Date*: 2008-02-08
    Sponsor Name:AstraZeneca AB
    Full Title: A 52-Week, International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study with a 156-Week Extension Period to Evaluate the Efficacy and Safety of Dapaglif...
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029505 Non-insulin-dependent diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) FR (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 11:17:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA